Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- ~13 hours (sc) in human PK models
- Unit
- mcg
- Administration Route
- Subcutaneous
- Frequency
- Daily or per protocol
- Last updated
- 2/17/2026
- Targets
- GLP1R, GCGR
Overview
—
Protocol
- Dosage Range
- Per trial protocol
- Frequency
- Daily or per protocol
- Cycle
- Per study
- Administration Route
- Subcutaneous
- Reconstitution Guide
- —
Science
Mechanism of Action
Dual agonism for glucose control and weight loss.
Targets
GLP1R, GCGR
Studies
- — Journal/year not available
Benefits
Weight lossGlycemic controlLiver health improvement
Potential Side Effects
- Nausea
- Vomiting
- Diarrhea
References
References coming soon.
Suggest a reference